Rutaecarpine exerted anti-osteroporosis
10.16438/j.0513-4870.2020-1616
- VernacularTitle:吴茱萸次碱抗骨质疏松作用研究
- Author:
Yi-ning LI
1
;
Xiao-wan HAN
2
;
Wei-zhi WANG
1
;
Xin-hai JIANG
1
;
Jiang-xue HAN
1
;
Jing ZHANG
1
;
Ni LI
2
;
Dong-sheng LI
1
;
Ren SHENG
1
;
Ye-xiang WU
1
;
Yang XU
1
;
Yu REN
1
;
Yan-ni XU
1
;
Shu-yi SI
1
Author Information
1. NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. NHC Key Laboratory of Biotechnology of Antibiotics, National Center for Screening Novel Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
osteoporosis;
rutaecarpine;
osteoprotegerin;
osteogenic differentiation;
osteoclastic differentiation;
ovariectomized rat
- From:
Acta Pharmaceutica Sinica
2021;56(2):511-519
- CountryChina
- Language:Chinese
-
Abstract:
Osteoprotegerin (OPG), secreted by osteoblasts, is a marker of bone turnover. OPG can inhibit osteoclastic differentiation by binding receptor activator of nuclear factor-κB ligand (RANKL). In this study, we found that rutaecarpine (RUT) had the up-regulating OPG activity, and it could significantly increase OPG protein levels in both mouse embryonic osteogenic precursor MC3T3-E1 and human osteosarcoma U-2OS cells. Osteoblastogenic differentiation calcified nodules staining results showed that RUT significantly promoted the osteogenic differentiation of MC3T3-E1 cells. Osteoclastic differentiation tartrate resistant acid phosphatase (TRAP) staining results showed that RUT obviously inhibited the osteoclast differentiation of mouse macrophages RAW264.7 induced by RANKL. In vivo studies showed that low-dose RUT group (5 mg·kg-1·day-1) and high-dose RUT group (45 mg·kg-1·day-1) treatments for 3 months significantly increased bone density in ovariectomized (OVX) rats; calcein double labeling experiment and toluidine blue staining results indicated that low-dose RUT group promoted bone formation and decreased bone loss in vivo; immunohistochemistry results showed that low-dose RUT group increased the expression of OPG in rat femur. All animal procedures were performed in accordance with the regulations of the Institutional Animal Care and Use Committee of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. In summary, this study demonstrated that RUT could up-regulate OPG expression and had promoting osteoblastic differentiation and inhibiting osteoclastic differentiation effects in vitro and in vivo.
